Danaher (NYSE:DHR) said today that its Leica Biosystems division agreed to buy Devicor Medical Products, a developer of breast biopsy products.
Leica Biosystems specializes in automated cancer diagnostics. Financial terms were not disclosed.
Devicor, which has around 400 employees worldwide, was created by private equity firm GTCR. In 2010, the company acquired the Mammotome breast-care business from Johnson & Johnson (NYSE:JNJ), which it eventually expanded with new product lines and markets.
"Leica Biosystems’ products and solutions address the key steps across the anatomic pathology workflow. The addition of Devicor’s market leading breast biopsy products, especially Mammotome, allows us to further integrate that workflow from the source, starting with the patient and the biopsy sample," CEO Dr. Matthias Weber said in prepared remarks. "This acquisition supports our mission of advancing cancer diagnostics to improve lives by adding products that will have direct benefits for the patients and the clinicians who care for them."
"Our partnership with Devicor CEO Tom Daulton and the carve-out of the Mammotome business from Johnson & Johnson is another example of how GTCR executes on the leaders strategy," added GTCR managing director Dean Mihas. "We created Devicor with the goal of acquiring and building a leading medical device company with an attractive market position and physician preferred products focused on interventional procedures. Since the initial carve-out acquisition, Tom and the team have successfully built a leading global platform in the breast biopsy market."
Last month, Danaher agreed to acquire dental-implant maker Nobel Biocare for approximately $2.14 billion.
